{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:23:11Z","timestamp":1787930591672,"version":"build-2784847793"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.therap.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:16:16Z","timestamp":1786576576000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and risk factors of severe cutaneous drug reactions and evaluation through available databases"],"prefix":"10.1016","author":[{"given":"Thomas","family":"Bettuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.08.001_bib0680","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions: a report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2026.08.001_bib0685","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0690","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0695","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","article-title":"Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey","volume":"52","author":"Hunziker","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.therap.2026.08.001_bib0700","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib0705","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0710","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0715","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case\u2013control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0720","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases","volume":"32","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Melanoma Res"},{"key":"10.1016\/j.therap.2026.08.001_bib0725","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaad.2020.10.091","article-title":"Changing spectrum of suspected drugs of Epidermal Necrolysis: an WHO pharmacovigilance database analysis from 1997 to 2020","volume":"85","author":"Bettuzzi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0730","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2026.08.001_bib0735","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2026.08.001_bib0740","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jid.2020.03.968","article-title":"Incidence of epidermal necrolysis: results of the German registry","volume":"140","author":"Naegele","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0745","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0750","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis) in France during 2003\u201316: a four-source capture\u2013recapture estimate","volume":"182","author":"Chaby","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0755","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in france, 1981\u20131985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0760","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","article-title":"Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation\u2014A retrospective chart review","volume":"81","author":"Weinkle","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0765","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jid.2023.09.274","article-title":"Validation of an algorithm to identify epidermal necrolysis on a medico-administrative database","volume":"144","author":"Bettuzzi","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0770","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/bjd\/ljae240","article-title":"Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study","volume":"191","author":"Bettuzzi","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0775","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamadermatol.2024.3575","article-title":"Incidence, in-hospital and long-term mortality, and sequelae of epidermal necrolysis in adults","volume":"160","author":"Bettuzzi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0780","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/bjd\/ljad234","article-title":"Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019","volume":"189","author":"Chiu","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0785","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0790","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jid.2017.05.010","article-title":"Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort","volume":"137","author":"Gillis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0795","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0800","first-page":"247","article-title":"Trends in mortality rates for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0805","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European Multicenter Study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0810","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.jid.2024.06.1295","article-title":"Diagnosing and managing Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in adults: review of evidence 2017\u20132023","volume":"145","author":"Ingen-Housz-Oro","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0815","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0820","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/ced\/llae553","article-title":"Recurrences and rechallenges of suspected drugs in patients with epidermal necrolysis","volume":"50","author":"Bettuzzi","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0825","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archdermatol.2008.521","article-title":"Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae","volume":"145","author":"Brown","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0830","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000112926","article-title":"Minocycline-Induced DRESS: evidence for accumulation of the culprit drug","volume":"216","author":"Maubec","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2026.08.001_bib0835","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/cod.70003","article-title":"Drug provocation testing in allergological work-up of DRESS: a retrospective real-life experience from a specialist centre","volume":"93","author":"Assier","year":"2025","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2026.08.001_bib0840","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.annder.2019.01.010","article-title":"Hypersensibilit\u00e9 retard\u00e9e aux traitements antituberculeux. Proposition d\u2019une conduite \u00e0 tenir pratique devant un exanth\u00e8me\u00a0: quand arr\u00eater, quelles explorations allergologiques et comment r\u00e9introduire le traitement","volume":"146","author":"Ingen-Housz-Oro","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0845","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamadermatol.2022.3541","article-title":"Risk factors for vancomycin drug reaction with eosinophilia and systemic symptoms syndrome","volume":"158","author":"Blumenthal","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0850","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction wit eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2026.08.001_bib0855","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","article-title":"Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study","volume":"82","author":"Soria","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0860","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000877","article-title":"Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases","volume":"33","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Melanoma Res"},{"key":"10.1016\/j.therap.2026.08.001_bib0865","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jaad.2023.05.067","article-title":"Drug reaction eosinophilia and systemic symptoms: clinical phenotypic patterns according to causative drug","volume":"90","author":"Blumenthal","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0870","doi-asserted-by":"crossref","first-page":"103381","DOI":"10.1016\/j.annder.2025.103381","article-title":"French national protocol for diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in adults and children","volume":"152","author":"Ingen-Housz-Oro","year":"2025","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0875","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.therap.2026.08.001_bib0880","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2026.08.001_bib0885","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.therap.2026.08.001_bib0890","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jdv.18808","article-title":"Management and treatment outcome of DRESS patients in Europe: an international multicentre retrospective study of 141 cases","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0895","doi-asserted-by":"crossref","first-page":"28492","DOI":"10.1038\/s41598-024-69054-7","article-title":"Viral reactivation and clinical outcomes in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"14","author":"Chan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2026.08.001_bib0900","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/jdv.19425","article-title":"Retrospective study on the association of human herpesvirus reactivation with severe DRESS: a description of blood and skin reactivations","volume":"37","author":"Marcombes","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0905","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.jaad.2010.11.057","article-title":"A review of DRESS-associated myocarditis","volume":"66","author":"Bourgeois","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0910","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0915","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1515\/jpem-2021-0685","article-title":"Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature","volume":"35","author":"Tempark","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.therap.2026.08.001_bib0920","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaad.2024.05.018","article-title":"Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: a pharmacovigilance study","volume":"91","author":"Matei","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0925","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1111\/jdv.20232","article-title":"Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management","volume":"38","author":"Tetart","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0930","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u00a0\u2013\u00a0A clinical reaction pattern: acute generalized exanthematous pustulosis","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.therap.2026.08.001_bib0935","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","article-title":"Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US","volume":"158","author":"Creadore","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0940","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/jdv.18940","article-title":"Acute generalized exanthematous pustulosis: clinico-biological profile and inducing drugs in 83 patients","volume":"37","author":"Weiss","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib0945","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0950","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2133.1990.tb06275.x","article-title":"Requiem for toxic epidermal necrolysis","volume":"122","author":"Lyell","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0955","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jfma.2021.09.025","article-title":"Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.therap.2026.08.001_bib0960","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jaip.2026.01.003","article-title":"Generalized bullous fixed drug eruption: a systematic review","volume":"14","author":"Loo","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2026.08.001_bib0965","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis: prognosis of GBFDE vs. SJS\/TEN","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0970","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"A marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.therap.2026.08.001_bib0975","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib0980","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib0985","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.therap.2026.08.001_bib0990","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.therap.2026.08.001_bib0995","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.seizure.2018.06.024","article-title":"Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis","volume":"60","author":"Deng","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.therap.2026.08.001_bib1000","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.anai.2017.02.011","article-title":"HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population","volume":"118","author":"Kim","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.therap.2026.08.001_bib1005","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug\u2013induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2026.08.001_bib1010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 Screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.therap.2026.08.001_bib1020","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.therap.2026.08.001_bib1025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.therap.2026.08.001_bib1030","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2025.4240","article-title":"HLA-B*58:01 and risk of allopurinol-induced severe cutaneous adverse reactions in the US","volume":"161","author":"Campbell","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2026.08.001_bib1045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 Screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1050","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2026.08.001_bib1055","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the Dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1060","doi-asserted-by":"crossref","first-page":"954596","DOI":"10.3389\/fphar.2022.954596","article-title":"Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2026.08.001_bib1065","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/jid.2013.44","article-title":"Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis","volume":"133","author":"Navarini","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1070","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36\u2013receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2026.08.001_bib1085","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.18422","article-title":"Factors influencing the incidence of lamotrigine-related skin rash","volume":"33","author":"Wong","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2026.08.001_bib1090","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0000000000001557","article-title":"Impact of selected initial titration schedules on safety and long-term effectiveness of lamotrigine for the treatment of mood disorders","volume":"42","author":"Nakamura","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2026.08.001_bib1095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-282X1996000100008","article-title":"Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk","volume":"54","author":"Li","year":"1996","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.therap.2026.08.001_bib1100","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.therap.2026.08.001_bib1105","series-title":"Lamotrigine (Lamictal et g\u00e9n\u00e9riques)\u202f: rappel du bon usage afin de limiter le risque d\u2019\u00e9ruption cutan\u00e9e grave en particulier au d\u00e9but du traitement","year":"2023"},{"key":"10.1016\/j.therap.2026.08.001_bib1110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JCP.0b013e3181845610","article-title":"The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study","volume":"28","author":"Gau","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2026.08.001_bib1115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/jhg.2015.47","article-title":"Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children","volume":"60","author":"Suvichapanich","year":"2015","journal-title":"J Hum Genet"},{"key":"10.1016\/j.therap.2026.08.001_bib1120","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1125","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2665-9913(25)00165-1","article-title":"Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1130","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2026.08.001_bib1135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate\u00a0\u2013\u00a0a complex drug interaction: implications for clinical practice","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.therap.2026.08.001_bib1140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2014.08.068","article-title":"Molecular mechanism of an adverse drug\u2013drug interaction of allopurinol and furosemide in gout treatment","volume":"452","author":"Knake","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2026.08.001_bib1145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1574886311308020004","article-title":"A comparison of adverse drug reactions between high- and standard- dose trimethoprim-sulfamethoxazole in the ambulatory setting","volume":"8","author":"Nguyen","year":"2013","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.therap.2026.08.001_bib1150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","article-title":"Pneumocystis carinii Pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies","volume":"100","author":"Kovacs","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1155","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2026.08.001_bib1160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-100-4-495","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome","volume":"100","author":"Gordin","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00002030-199301000-00010","article-title":"Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients:","volume":"7","author":"Carr","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2026.08.001_bib1170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0163-4453(99)90078-6","article-title":"Desensitization to co-trimoxazole (trimethoprimsulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction?","volume":"38","author":"Gompels","year":"1999","journal-title":"J Infect"},{"key":"10.1016\/j.therap.2026.08.001_bib1175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0091-6749(98)70343-4","article-title":"Six-hour trimethoprim-sulfamethoxazole\u2013graded challenge in HIV-infected patients","volume":"102","author":"Demoly","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2026.08.001_bib1180","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1542\/peds.2012-1575","article-title":"Incidence of rash after amoxicillin treatment in children with infectious mononucleosis","volume":"131","author":"Chovel-Sella","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2026.08.001_bib1185","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/cid\/cit553","article-title":"Do penicillins really increase the frequency of a rash when given during Epstein-Barr virus primary infection?","volume":"57","author":"Hocqueloux","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2026.08.001_bib1190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1195","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jaad.2018.10.058","article-title":"Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients\u2019 characteristics","volume":"80","author":"Chaby","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljad226","article-title":"Comparison of idiopathic and drug-induced epidermal necrolysis in children","volume":"189","author":"Welfringer-Morin","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1205","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jamaoncol.2025.4349","article-title":"Immune checkpoint inhibitors as independent and synergistic drivers of SJS\/TEN","volume":"11","author":"Mukherjee","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.therap.2026.08.001_bib1210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cod.14810","article-title":"Positive osimertinib patch test in a bullous lichenoid drug reaction","volume":"93","author":"Marcombes","year":"2025","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2026.08.001_bib1215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.therap.2026.08.001_bib1220","series-title":"New drug therapy approvals","year":"2024"},{"key":"10.1016\/j.therap.2026.08.001_bib1225","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Nor\u00e9n","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Les \u00e9tudes cas\u2013non cas\u00a0: principe, m\u00e9thodes, biais et interpr\u00e9tations","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.08.001_bib1235","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.therap.2026.08.001_bib1240","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u00a0\u2013\u00a0a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.therap.2026.08.001_bib1245","first-page":"298","volume":"94","author":"Mahajan","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1250","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.2013.276938","article-title":"FDA: acetaminophen may trigger serious skin problems","volume":"310","author":"Kuehn","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2026.08.001_bib1255","series-title":"Questions and answers: FDA warns of rare but serious skin reactions with the pain reliever\/fever reducer acetaminophen","author":"Food and Drug","year":"2015"},{"key":"10.1016\/j.therap.2026.08.001_bib1260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bcp.13445","article-title":"Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database: risk of Stevens-Johnson syndrome and toxic epidermal necrolysis with acetaminophen","volume":"84","author":"Lebrun-Vignes","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.08.001_bib1265","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.08.001_bib1270","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.sapharm.2025.02.008","article-title":"Artificial intelligence (AI) in pharmacovigilance: a systematic review on predicting adverse drug reactions (ADR) in hospitalized patients","volume":"21","author":"Dsouza","year":"2025","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.therap.2026.08.001_bib1275","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug\u2013drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.therap.2026.08.001_bib1280","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1111\/jdv.20599","article-title":"Automated detection of in-hospital drug hypersensitivity reactions using a privacy-preserving large language model","volume":"39","author":"Dezoteux","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib1285","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaip.2018.12.012","article-title":"Efficacy of the HLA-B*58:01 Screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency\u2014A prospective study","volume":"7","author":"Park","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2026.08.001_bib1290","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2026.08.001_bib1295","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.therap.2025.02.013","article-title":"Cutaneous adverse drug reactions induced by anticonvulsants: proposal for allergological work-up and contraindications","volume":"80","author":"Ingen-Housz-Oro","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.08.001_bib1300","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2026.08.001_bib1305","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/derm.2023.0291","article-title":"Skin testing and drug provocation tests should be performed in the context of drug reaction with eosinophilia and systemic symptoms: a cohort study","volume":"35","author":"Toulemonde","year":"2024","journal-title":"Dermatitis"},{"key":"10.1016\/j.therap.2026.08.001_bib1310","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.jaip.2022.07.008","article-title":"Skin testing and drug provocation tests in epidermal necrolysis: a French experience","volume":"10","author":"Roux","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2026.08.001_bib1315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/cod.14654","article-title":"Patch tests in non-immediate cutaneous adverse drug reactions: late readings on Day 4 is more sensitive than on Day 3","volume":"91","author":"Matei","year":"2024","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2026.08.001_bib1320","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","article-title":"Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System","volume":"9","author":"Bluestein","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2026.08.001_bib1325","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1111\/jdv.20662","article-title":"Severe adverse drug reactions induced by lamotrigine: are prescription guidelines being followed?","volume":"39","author":"Thorn","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2026.08.001_bib1330","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fphar.2017.00879","article-title":"Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population","volume":"8","author":"Koomdee","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2026.08.001_bib1335","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FPC.0b013e32832c347d","article-title":"High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients","volume":"19","author":"Kazeem","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.therap.2026.08.001_bib1340","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","article-title":"HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS\/TEN according to culprit drugs","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.therap.2026.08.001_bib1345","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/pgs.14.69","article-title":"HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population","volume":"15","author":"Yang","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.therap.2026.08.001_bib1350","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2020.04.056","article-title":"Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A*32:01\u2013positive vancomycin-induced DRESS sharing an HLA class II haplotype","volume":"147","author":"Nakkam","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:44:53Z","timestamp":1787928293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":135,"alternative-id":["S0040595726000818"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.08.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and risk factors of severe cutaneous drug reactions and evaluation through available databases","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}